Gram-negative Bacteremia
12
3
3
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
A Platform Trial for Gram Negative Bloodstream Infections
Impact of Real-time MIC (Minimum Inhibitory Concentration) Reporting (<6 Hours) on β-lactam Prescription in Cases of Gram-negative Bacilli Bacteremia in ICU Patients in Real-life Settings
Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial
BALANCE+ Vanguard Phase
CRP and PCT as Predictors of Sepsis Cause
Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia
Clinical Impact of Fast Phenotypic Antimicrobial Susceptibility Testing on Patients With Gram-Negative Rod Bacteremia
Comparison of Solid Organ Transplant
Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia
Clinical Outcomes and Cost of Gram Negative Bacteremia